Alexis Khalil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexis Khalil has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Alfonso Quintás-Cardama
Foghorn Therapeutics Inc.; Watertown, MA, USA
50 shared publications - Michael Patrick Collins
Foghorn Therapeutics, Cambridge, MA
49 shared publications - Sarah A. Reilly
Foghorn Therapeutics Inc.; Watertown, MA, USA
49 shared publications - Denice Hickman
Foghorn Therapeutics Inc., Cambridge, Massachusetts
48 shared publications - Jessica Piel
Foghorn Therapeutics Inc., Cambridge, Massachusetts
48 shared publications - Kathleen Healy
Foghorn Therapeutics Inc., Cambridge, Massachusetts
48 shared publications
Latest Publications
- Open Access
Mechanism of response to FHD-286 and decitabine combination in patients with advanced myeloid malignancies
Impaired cellular differentiation is a defining characteristic of myeloid malignancies and remains a major therapeutic challenge. The BRG1/Brahma-associated factor (BAF) chromatin remodeling complex, through the ATPases SMARCA4 and SMARCA2, maintains the stemness of leukemic blasts and thus represents a promising target for novel differentiation-based therapies. In a phase 1 study in advanced myeloid malignancies, the first-in-class dual SMARCA4/2 inhibitor FHD-286 combined with decitabine (DAC) was tolerated and produced an objective response rate of 12.8% (6/47) compared with no responses with FHD-286 monotherapy. To understand the basis of this activity, we integrated high-dimensional flow cytometry and single-cell genomic analyses of longitudinal bone marrow samples from responders and nonresponders. While FHD-286 monotherapy was predominantly associated with myeloid differentiation, responders to FHD-286+DAC combination therapy exhibited a range of myeloid and erythroid differentiation trajectories. FHD-286 potentiated the transcriptional impact of DAC, driving tumor clones to fully differentiate out of the immunophenotypically and transcriptionally defined blast compartment. Responders had a baseline transcriptional profile similar to that of CEBPA -mutant acute myeloid leukemia and showed further downregulation of CEBPA upon treatment. These findings reinforce tumor cell differentiation as a mechanism of response to pharmacologic SMARCA4/2 inhibition and support further evaluation of FHD-286+DAC in molecularly defined patient subsets. ONE SENTENCE SUMMARY: In a phase 1 R/R AML study, FHD-286 potentiated the effects of decitabine to promote responses via tumor cell differentiation and CEBPA perturbation.
Open AccessMechanism of response to FHD-286 and decitabine combination in patients with advanced myeloid malignancies
Impaired cellular differentiation is a defining characteristic of myeloid malignancies and remains a major therapeutic challenge. The BRG1/Brahma-associated factor (BAF) chromatin remodeling complex, through the ATPases SMARCA4 and SMARCA2, maintains the stemness of leukemic blasts and thus represents a promising target for novel differentiation-based therapies. In a phase 1 study in advanced myeloid malignancies, the first-in-class dual SMARCA4/2 inhibitor FHD-286 combined with decitabine (DAC) was tolerated and produced an objective response rate of 12.8% (6/47) compared with no responses with FHD-286 monotherapy. To understand the basis of this activity, we integrated high-dimensional flow cytometry and single-cell genomic analyses of longitudinal bone marrow samples from responders and nonresponders. While FHD-286 monotherapy was predominantly associated with myeloid differentiation, responders to FHD-286+DAC combination therapy exhibited a range of myeloid and erythroid differentiation trajectories. FHD-286 potentiated the transcriptional impact of DAC, driving tumor clones to fully differentiate out of the immunophenotypically and transcriptionally defined blast compartment. Responders had a baseline transcriptional profile similar to that of CEBPA -mutant acute myeloid leukemia and showed further downregulation of CEBPA upon treatment. These findings reinforce tumor cell differentiation as a mechanism of response to pharmacologic SMARCA4/2 inhibition and support further evaluation of FHD-286+DAC in molecularly defined patient subsets. ONE SENTENCE SUMMARY: In a phase 1 R/R AML study, FHD-286 potentiated the effects of decitabine to promote responses via tumor cell differentiation and CEBPA perturbation.
- Open Access
- 12 December 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (24) , e71442
Prognostic Implications of SMARCA4 , ARID1A , and Other BAF Mutations in Non‐Small Cell Lung Cancer
Background and Methods: Non‐small cell lung cancer (NSCLC) outcomes have improved remarkably with the widespread use of immune checkpoint inhibitors and small molecule inhibitors targeting driver mutations. Nevertheless, many patients continue to experience suboptimal outcomes. The prevalence of mutations in the BAF (BRG1/BRM‐associated factor) chromatin remodeling complexes may represent an opportunity to help close this gap: These critical regulators of chromatin accessibility are mutated in approximately a quarter of NSCLC cases, and numerous retrospective reports have evaluated the impact of these mutations on clinical outcomes. Here, we appraise the varying and occasionally divergent evidence for BAF complex mutations as predictive and prognostic biomarkers in NSCLC. Results: We conclude that these mutations hold promise as refinements to existing prognostic and treatment algorithms, with SMARCA4 mutations imparting poor prognosis, ARID1A mutations predicting better prognosis with immune checkpoint inhibitor therapy, and ARID1A ‐epithelial growth factor receptor ( EGFR ) comutations being associated with insensitivity to EGFR tyrosine kinase inhibitor therapy. Additional research should focus on large, prospective studies that will allow better quantification of the impact of BAF complex mutations. Conclusions: A growing body of evidence indicates that BAF complex mutations have important prognostic implications. These may be leveraged for risk stratification and therapeutic selection in patients with non‐small cell lung cancer.
- 12 December 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (24) , e71442
Open AccessPrognostic Implications of SMARCA4 , ARID1A , and Other BAF Mutations in Non‐Small Cell Lung Cancer
Background and Methods: Non‐small cell lung cancer (NSCLC) outcomes have improved remarkably with the widespread use of immune checkpoint inhibitors and small molecule inhibitors targeting driver mutations. Nevertheless, many patients continue to experience suboptimal outcomes. The prevalence of mutations in the BAF (BRG1/BRM‐associated factor) chromatin remodeling complexes may represent an opportunity to help close this gap: These critical regulators of chromatin accessibility are mutated in approximately a quarter of NSCLC cases, and numerous retrospective reports have evaluated the impact of these mutations on clinical outcomes. Here, we appraise the varying and occasionally divergent evidence for BAF complex mutations as predictive and prognostic biomarkers in NSCLC. Results: We conclude that these mutations hold promise as refinements to existing prognostic and treatment algorithms, with SMARCA4 mutations imparting poor prognosis, ARID1A mutations predicting better prognosis with immune checkpoint inhibitor therapy, and ARID1A ‐epithelial growth factor receptor ( EGFR ) comutations being associated with insensitivity to EGFR tyrosine kinase inhibitor therapy. Additional research should focus on large, prospective studies that will allow better quantification of the impact of BAF complex mutations. Conclusions: A growing body of evidence indicates that BAF complex mutations have important prognostic implications. These may be leveraged for risk stratification and therapeutic selection in patients with non‐small cell lung cancer.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 5. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 39; R/R AML; FHD-286 7.5 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 5. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 39; R/R AML; FHD-286 7.5 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 6. FHD-286 induced myeloid differentiation. Genetic and mutational profiles of patients for whom matched bone marrow samples at screening and on FHD-286 were analyzed.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Table 6. FHD-286 induced myeloid differentiation. Genetic and mutational profiles of patients for whom matched bone marrow samples at screening and on FHD-286 were analyzed.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 8. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 15; R/R AML; FHD-286 10 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 8. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 15; R/R AML; FHD-286 10 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 10. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by parameter.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 10. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by parameter.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 3. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 29; R/R AML; 5 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 3. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 29; R/R AML; 5 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 9. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by patient.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 9. Bone marrow blasts, peripheral blasts, and absolute neutrophil counts over time in patients with >50% reduction in bone marrow blasts from baseline, by patient.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 7. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 13; R/R AML; FHD-186 10 mg QD dose group.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 7. Blast percentage, hemoglobin level, leukocyte count, neutrophil count, platelet count over time, and total daily dose exposure for patient 13; R/R AML; FHD-186 10 mg QD dose group.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 14. Single-cell genomic data set characteristics. A) Dot plot showing expression of key cell type-specific marker genes.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies
Supplementary Figure 14. Single-cell genomic data set characteristics. A) Dot plot showing expression of key cell type-specific marker genes.